Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leuk...
Saved in:
Main Author: | Maiko Matsushita |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
by: Emole J, et al.
Published: (2016) -
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
by: Haidée Aranda-Tavío, et al.
Published: (2021) -
Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient
by: Majid Marjani, et al.
Published: (2014) -
Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
by: Panagiotis T. Diamantopoulos, et al.
Published: (2021) -
Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study
by: Terry C. Davis, et al.
Published: (2021)